Study | Cementless TKA (n) | Follow-up (y) | Survivorship % at last follow-up (aseptic) | Survivorship % at last follow-up (all-cause) | Type of study |
---|---|---|---|---|---|
Harwin et al (2013) [34] | 114 | 3 | 100.0% | 100.0% | Prospective Consecutive Series |
Harwin et al (2015) [36] | 1025 | 4 | 99.6% | 99.1% | Prospective Consecutive Series |
Bagsby et al (2016) [11] | 145 | 3.65 | 98.0% | 98.0% | Multicenter Review |
Harwin et al (2017) [39] | 1024 | 4.4 | 99.5% | 99.5% | Retrospective Review |
Miller et al (2017) [41] | 200 | 2.3 | 96.5% | 96.5% | Retrospective Matched Case–Control |
Mont et al (2017) [37] | 31 | 4 | 100.0% | 100.0% | Retrospective Review of Prospectively Collected Database |
Newman et al (2017) [32] | 142 | 4 | 99.3% | 98.6% | Prospective Review |
Sultan et al (2017) [30] | 49 | 3.8 | 97.9% | 96% | Prospective Review |
Van Hamersveld et al (2017) [21] | 30 | 5 | 100.0% | 100.0% | 5Â yr Follow-Up of a Randomized Control Trial |
Nam et al (2017) [40] | 66 | 1.4 | 100.0% | 100.0% | Retrospective Review of a Consecutive Series |
Harwin et al (2017) [29] | 107 | 8 | 100.0% | 100.0% | Prospective Consecutive Series |
Boyle et al (2018) [43] | 154 | 5.9 | 99.4% | 98.1% | Retrospective Review |
Cohen et al (2018) [33] | 72 | 3 | 100.0% | 100.0% | Non-Randomized Prospective Review |
Patel et al (2018) [38] | 126 | 4 | 99.2% | 99.2% | Retrospective Review |
Sinicrope et al (2019) [35] | 108 | 5.9 | 100.0% | 100.0% | Retrospective Review |
Nam et al (2019) [20] | 76 | 2.1 | 99.0% | 99.0% | Prospective Randomized Control Trial |
Sultan et al (2020) [31] | 568 | 3 | 98.2% | 98.2% | Retrospective Review |
Yazdi et al (2020) [42] | 699 | 2.76 | 99.3% | 99.3% | Retrospective Review |
Hasan et al (2020) [45] | 35 | 2 | 97.1% | 97.1% | Randomized Control Trial |
Restrepo et al (2021) [44] | 341 | 5.5 | 97.1% | 97.1% | Retrospective Registry Review |